A Study of Imvotamab in Severe Systemic Lupus Erythematosus

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

January 27, 2025

Study Completion Date

January 27, 2025

Conditions
Systemic Lupus ErythematosusLupus Erythematosus
Interventions
DRUG

Imvotamab

Administered intravenously

Trial Locations (10)

32713

Omega Research, DeBary, DeBary

33324

Integral Rheumatology & Immunology Specialists, Plantation

75013

Stryde Research, Allen

76051

Precision Comprehensive Clinical Research, Grapevine

77054

Prolato Clinical Research Center, Houston

77090

Care and Cure Clinic, Houston

92108

TriWest Research Associates, San Diego

94578

East Bay Rheumatology, San Leandro

Unknown

Niepubliczny Zakład Opieki Zdrowotnej Lecznica MAK-MED w Nadarzynie, Nadarzyn

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

IGM Biosciences, Inc.

INDUSTRY